Light Therapy as Treatment for Fatigue in Multiple Sclerosis
Primary Purpose
Multiple Sclerosis, Relapsing-Remitting
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Light Therapy box
Sponsored by
About this trial
This is an interventional treatment trial for Multiple Sclerosis, Relapsing-Remitting focused on measuring Multiple Sclerosis, Relapsing-Remitting Multiple Sclerosis, Fatigue, Light Therapy
Eligibility Criteria
Inclusion Criteria:
- Relapsing remitting Multiple Sclerosis based on the McDonald Criteria (2010)
- Over 18 years old
- Presence of fatigue defined as FSS over 36
Exclusion Criteria:
- A change in an anti-depressant up to 4 weeks prior to study screening
- A change in fatigue medication regime or MS disease modifying therapy up to 4 weeks prior to study screening
- Shift work
- Use of photosensitizing medication
- Presence of eye trauma or acute optic neuritis within the preceding 3 months
- History of traumatic brain injury
- Probable (untreated) sleep apnea based on Berlin questionnaire
- Significant anemia
- History of mania
- MS relapse in the preceding four weeks
- Current pregnancy
- Known light sensitivity
- Other complicating illness preventing study completion.
Sites / Locations
- Massachusetts General Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Light Therapy-Spectrum 1
Light Therapy-Spectrum 2
Arm Description
Light from 'active' spectrum
Light from 'placebo' spectrum
Outcomes
Primary Outcome Measures
Change in Average Fatigue Severity Scale (FSS) Score
Measure of general level of fatigue. Range: 9 to 63. Lower scores indicate less reported fatigue.
Secondary Outcome Measures
Full Information
NCT ID
NCT03060759
First Posted
February 19, 2017
Last Updated
May 12, 2020
Sponsor
Massachusetts General Hospital
1. Study Identification
Unique Protocol Identification Number
NCT03060759
Brief Title
Light Therapy as Treatment for Fatigue in Multiple Sclerosis
Official Title
Light Therapy as Treatment for Fatigue in Multiple Sclerosis
Study Type
Interventional
2. Study Status
Record Verification Date
May 2020
Overall Recruitment Status
Completed
Study Start Date
April 1, 2017 (Actual)
Primary Completion Date
June 30, 2019 (Actual)
Study Completion Date
November 4, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Massachusetts General Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This prospective study will randomize 1:1 people living with multiple sclerosis-associated fatigue to one of two spectra of light therapy. Each participant will be asked to use the light box twice daily at home or at the workplace at preset hours during the day for a total of four weeks. Participants will be asked to record their fatigue on standard measurement scales before, during, and after the use of the light therapy box. The investigators anticipate a reduction in self-reported fatigue following the use of the light box therapy of a particular spectrum of light among people living with multiple sclerosis.
Detailed Description
Study Protocol:
Eligible participants will be consented and randomized 1:1 to (a) white LT (10,000 lux), or (b) dim red LT (<300 lux). Participants will be informed that this study will examine the effect of two different light spectra on fatigue. The following assessments will be administered by the study principal investigator at the baseline visit: (1) the Kurtzke Extended Disability Status Scale (EDSS), (2) FSS, (3) Beck Depression Inventory II (BDI), (4) Pittsburgh Sleep Quality Index (PSQI), (5) Berlin questionnaire for obstructive sleep apnea, (6) Epworth Sleepiness Scale. A two-week sleep diary will be collected before enrollment in order to screen for significant behavioral insufficient sleep or circadian rhythm disorders. The light box used for LT is designed to stand on a desk or tabletop. It can be used in the home or office. The light is delivered at a downward angle to maximize the effectiveness. The box runs on 124 watts and contains full spectrum 5000k 10,000 lux bulbs. Bright light treatment requires at least 2,500 lux to be effective.
Data Collection:
The study period will include a two-week baseline period, a four-week treatment period, and a four-week follow up period. Throughout the study period, participants will record their fatigue using the Visual Analogue Fatigue Scale (VAFS) four times daily, starting after waking up, and every four hours thereafter. The VAFS is a simple, validated 10-point scale ranging from 1 to 10 in which participants can report their fatigue as a snapshot at that particular moment. Data collection will occur by participants in self-report fashion. A FSS score will be collected at enrollment as well as at the end of the four week treatment period and the end of the four week follow-up period. There will be three visits with a principal investigators (PI), including the baseline visit described above, a visit with the PI at the end of the treatment period in which participants will report a FSS and discuss their experiences with LT, and a third follow-up visit at the end of the four-week follow up period for a final FSS. At this last visit they will be queried on whether they believe the intervention had any effect on their fatigue and whether they believe the alternative therapy (white light or dim red light) would have been more or less beneficial. Additionally participants will be asked to keep a LT log in which they will record daily LT exposure and associated side effects.
Statistical Analysis:
The primary outcome measure is the change in the average FSS after the four-week study period in the bright light "active" vs. dim light "control" groups. There are no reports on FSS in response to bright LT in pMS. Using the conventional values of α=0.05 and β=0.80 for 2-tailed tests of probability with equally sized groups: a difference in 10 points on FSS between groups requires 18 people per study arm; a difference in 8 points requires 28 people per group. If power is reduced to 70%, the sample sizes are 22 and 14 for 8-point and 10-point differences. First, the investigators will compare the mean change in FSS scores, from baseline to after completion of LT, in an intention to treat analysis. The secondary outcome measure will be a change in the global VAFS scores after light therapy in both groups. Frequencies will be used to describe baseline characteristics across treatment arms. X2 statistics or Fisher's exact test will be used to compare the differences between groups. VAFS will be evaluated using a mixed-effects model which accounts for correlation between repeated measurements. Participant logbooks will be used to generate summary statistics and graphically display fatigue patterns throughout the day. Logbooks will also qualitatively assess the safety and tolerability of LT.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Multiple Sclerosis, Relapsing-Remitting
Keywords
Multiple Sclerosis, Relapsing-Remitting Multiple Sclerosis, Fatigue, Light Therapy
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
35 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Light Therapy-Spectrum 1
Arm Type
Active Comparator
Arm Description
Light from 'active' spectrum
Arm Title
Light Therapy-Spectrum 2
Arm Type
Placebo Comparator
Arm Description
Light from 'placebo' spectrum
Intervention Type
Device
Intervention Name(s)
Light Therapy box
Intervention Description
The light box used for LT (SunRay by The Sunbox Company, Gaithersburg, Maryland, USA) is approximately 15.5" tall x 23" wide x 3.25" deep and is designed to stand on a desk or tabletop. It can be used both in the home or office. The light is delivered at a downward angle to maximize the effectiveness. The box runs on 124 watts and contains full spectrum 5000k 10,000 lux bulbs.
Primary Outcome Measure Information:
Title
Change in Average Fatigue Severity Scale (FSS) Score
Description
Measure of general level of fatigue. Range: 9 to 63. Lower scores indicate less reported fatigue.
Time Frame
4 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Relapsing remitting Multiple Sclerosis based on the McDonald Criteria (2010)
Over 18 years old
Presence of fatigue defined as FSS over 36
Exclusion Criteria:
A change in an anti-depressant up to 4 weeks prior to study screening
A change in fatigue medication regime or MS disease modifying therapy up to 4 weeks prior to study screening
Shift work
Use of photosensitizing medication
Presence of eye trauma or acute optic neuritis within the preceding 3 months
History of traumatic brain injury
Probable (untreated) sleep apnea based on Berlin questionnaire
Significant anemia
History of mania
MS relapse in the preceding four weeks
Current pregnancy
Known light sensitivity
Other complicating illness preventing study completion.
Facility Information:
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Light Therapy as Treatment for Fatigue in Multiple Sclerosis
We'll reach out to this number within 24 hrs